Houston, Texas — (December 2, 2025) — GreenJay Therapeutics, Inc. (“GreenJay” or the “Company”), a late-stage pharmaceutics company developing potentially life-changing technologies for patients that require stem cell or bone marrow transplantation. The Company announced today the appointment of Vassil Tzenov as Vice President and Chief Financial Officer. Mr. Tzenov will lead and manage the financial requirements of the Company.
Mr. Tzenov brings more than 18 years of U.S. and international finance leadership experience across the biotechnology, pharmaceutical, and manufacturing sectors. He will oversee GreenJay’s financial strategy and planning as the company advances its lead program through clinical development and toward commercialization.
Mr. Tzenov’s extensive experience building financial infrastructure in high-growth biotech environments makes him an invaluable addition to our leadership team,” said Michael T. Redman, President & Chief Executive Officer of GreenJay . “His track record in strategic planning, cost optimization, and capital management will be instrumental as GreenJay moves through its next phase of growth and prepares for key regulatory milestones.”
Prior to joining GreenJay, Mr. Tzenov held senior finance roles at Bayer Healthcare, Novartis, Amyris, and Neurona Therapeutics, where he led global financial operations, implemented ERP and cost-control systems, and spearheaded major efficiency initiatives. Mr. Tzenov holds a Master of Business Administration from the University of San Francisco School of Management and a Bachelor of Science from Sonoma State University. He is also certified Greenbelt Expert in Operational Excellence.
GreenJay has recently completed its Series A financing and is preparing necessary documentation to submit for FDA marketing approval. The lead product in development is Bulanta TM , for the treatment of Chronic Myeloid Leukemia (CML) and other blood cancers and disorders.
About GreenJay
GreenJay Therapeutics, Inc. is a drug formulation company focused on developing drug products with greater drug solubility, improved safety profiles and greater efficacy. The Company’s lead product candidate, BULANTA (IV busulfan), is being developed as an alternative to other IV formulations of busulfan that contain the toxic DMA solvent. BULANTA is in late-stage development for treatment as a conditioning agent for stem cell transplantation. For more information, please visit the Company’s web site at www.greenjaytherapeutics.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of GreenJay’s product candidates, alone and in combination with other therapies, on leukemia and other blood diseases, regarding potential, current and planned clinical trials, regarding the Company’s future growth and financial status and regarding our commercial partnerships. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of BULANTA and our other potential product candidates including whether we receive fast track or similar regulatory designations; and costs associated with developing our product candidates.
All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
GreenJay Therapeutics, Inc.
mredman@greenjaytherapeutics.com